Overview Financials News + Filings Key Docs Charts Holdings Ownership
|
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Immunology | 4,370.3 | 2,827.0 | 1,062.7 | | | | | |
| Hematology | 3,785.6 | 2,240.8 | | | | | | |
| Neuroscience | 2,664.1 | 2,490.5 | 2,200.4 | 2,204.5 | 1,603.2 | 1,458.8 | 1,337.8 | |
| Internal Medicine | 1,670.3 | 1,755.5 | 1,500.6 | 1,298.8 | 809.5 | 265.8 | 251.4 | |
| Other | 2,670.3 | 2,082.8 | 1,653.0 | 2,518.8 | 2,521.6 | 2,802.8 | 2,568.9 | |
| Total revenues [+] | 15,160.6 | 11,396.6 | 6,416.7 | 6,022.1 | 4,934.3 | 4,527.4 | 4,158.1 | 4,158.1 |
| Royalties | 711.7 | 510.8 | 316.8 | 191.7 | 153.7 | 241.6 | 283.5 | |
| Products | 14,448.9 | 10,885.8 | 6,099.9 | 5,830.4 | 4,757.5 | 4,252.9 | 3,844.9 | |
| Other | | | | | 23.1 | 32.9 | 29.7 | |
| Revenue growth [+] | 33.0% | 77.6% | 6.6% | 22.0% | 9.0% | 8.9% | 0.0% | 38.2% |
| Immunology | 54.6% | 166.0% | | | | | | |
| Hematology | 68.9% | | | | | | | |
| Neuroscience | 7.0% | 13.2% | -0.2% | 37.5% | 9.9% | 9.0% | | |
| Internal Medicine | -4.9% | 17.0% | 15.5% | 60.4% | 204.6% | 5.7% | | |
| Genetic Diseases | 3.6% | 3.8% | -42.6% | 46.3% | 12.2% | 15.4% | | |
| Cost of goods sold | 4,700.8 | 3,816.5 | 969.0 | 979.3 | 670.8 | 585.8 | 551.7 | 551.7 |
| Gross profit | 10,459.8 | 7,580.1 | 5,447.7 | 5,042.8 | 4,263.5 | 3,941.6 | 3,606.4 | 3,606.4 |
| Gross margin | 69.0% | 66.5% | 84.9% | 83.7% | 86.4% | 87.1% | 86.7% | 86.7% |
| Selling, general and administrative | 3,530.9 | 3,015.2 | 1,842.5 | 1,782.0 | 1,651.3 | 1,948.0 | 1,675.7 | 1,675.7 |
| Research and development | 1,763.3 | 1,439.8 | 1,564.0 | 1,067.5 | 933.4 | 953.0 | 764.5 | |
| Equity in earnings | 2.5 | -8.7 | -2.2 | 2.7 | 3.9 | 1.0 | 2.5 | 2.5 |
| Other operating expenses | 1,889.1 | 1,184.5 | 348.8 | 258.5 | -350.9 | -9.2 | 6.0 | 770.6 |
| EBITDA [+] | 5,543.2 | 3,398.2 | 2,327.4 | 2,344.8 | 2,358.0 | 1,359.4 | 1,457.5 | |
| EBITDA growth | 63.1% | 46.0% | -0.7% | -0.6% | 73.5% | -6.7% | 25.4% | 32.7% |
| EBITDA margin | 36.6% | 29.8% | 36.3% | 38.9% | 47.8% | 30.0% | 35.1% | 28.0% |
| Depreciation | 495.8 | 292.9 | 138.5 | 163.5 | 324.4 | 308.6 | 294.8 | |
| EBITA | 5,047.4 | 3,105.3 | 2,188.9 | 2,181.3 | 2,033.6 | 1,050.8 | 1,162.7 | 1,162.6 |
| EBITA margin | 33.3% | 27.2% | 34.1% | 36.2% | 41.2% | 23.2% | 28.0% | 28.0% |
| Amortization of intangibles | 1,768.4 | 1,173.4 | 498.7 | 243.8 | | | | |
| EBIT [+] | 3,279.0 | 1,931.9 | 1,690.2 | 1,937.5 | 2,033.6 | 1,050.8 | 1,162.7 | 1,162.6 |
| EBIT growth | 69.7% | 14.3% | -12.8% | -4.7% | 93.5% | -9.6% | 0.0% | 85.8% |
| EBIT margin | 21.6% | 17.0% | 26.3% | 32.2% | 41.2% | 23.2% | 28.0% | 28.0% |
| Non-recurring items [+] | 821.3 | 977.7 | 272.9 | 236.8 | 296.2 | 4.6 | 24.4 | 24.3 |
| Asset impairment | | | | | 198.9 | | | |
| Loss (gain) on sale of assets | -0.4 | -16.5 | -14.7 | -88.2 | -15.9 | -18.1 | | |
| Interest expense, net [+] | 569.2 | 451.2 | 37.4 | 6.1 | 36.0 | 35.2 | 37.2 | 37.2 |
| Interest expense | 578.9 | 469.6 | 41.6 | 30.8 | 38.1 | 38.2 | 39.1 | 39.1 |
| Interest income | 9.7 | 18.4 | 4.2 | 24.7 | 2.1 | 3.0 | 1.9 | 1.9 |
| Other income (expense), net [+] | 4.9 | -16.9 | 5.9 | 1,641.6 | -7.8 | -3.2 | 16.0 | -455.3 |
| Other | 7.4 | -25.6 | 3.7 | 8.9 | -3.9 | -2.2 | 18.5 | |
| Pre-tax income | 1,893.4 | 486.1 | 1,385.8 | 3,336.2 | 1,693.6 | 1,007.8 | 1,117.1 | 645.8 |
| Income taxes | -2,357.6 | -126.1 | 46.1 | -56.1 | -277.9 | -203.1 | -236.9 | -236.9 |
| Tax rate | | | 3.3% | | | | | |
| Earnings from continuing ops | 4,235.5 | 879.6 | 1,371.6 | 3,160.1 | 2,174.1 | 866.0 | 900.4 | 882.7 |
| Earnings from discontinued ops | 18.0 | -276.1 | -34.1 | 122.7 | -754.5 | -60.3 | -17.7 | -17.7 |
| Net income | 4,253.5 | 603.5 | 1,337.5 | 3,282.8 | 1,419.6 | 805.7 | 882.7 | 865.0 |
| Net margin | 28.1% | 5.3% | 20.8% | 54.5% | 28.8% | 17.8% | 21.2% | 20.8% |
| |
| Basic EPS [+] | $4.67 | $1.14 | $2.32 | $5.39 | $3.94 | $1.56 | $1.63 | |
| Growth | 309.1% | -50.8% | -56.9% | 36.8% | 152.6% | -4.6% | | |
| Diluted EPS [+] | $4.64 | $1.13 | $2.31 | $5.34 | $3.68 | $1.46 | $1.51 | |
| Growth | 309.8% | -51.0% | -56.7% | 45.1% | 152.4% | -3.5% | | |
| |
| Dividends per share [+] | $0.31 | $0.22 | $0.23 | $0.21 | $0.17 | $0.16 | $0.13 | |
| Growth | 39.5% | -2.3% | 8.4% | 20.2% | 12.4% | 16.0% | | -100.0% |
| |
| Shares outstanding (basic) [+] | 906.5 | 770.1 | 590.4 | 586.7 | 552.0 | 555.4 | 551.1 | |
| Growth | 17.7% | 30.4% | 0.6% | 6.3% | -0.6% | 0.8% | | |
| Shares outstanding (diluted) [+] | 912.0 | 776.2 | 593.1 | 591.3 | 590.3 | 593.5 | 595.4 | |
| Growth | 17.5% | 30.9% | 0.3% | 0.2% | -0.5% | -0.3% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|